Clinical Trial: FMXIN002 in Patients at Risk of Anaphylaxis

U.S., July 2 -- ClinicalTrials.gov registry received information related to the study (NCT07045701) titled 'FMXIN002 in Patients at Risk of Anaphylaxis' on June 08.

Brief Summary: Study Objective To evaluate the efficacy of FMXIN002, a powder-based intranasal epinephrine spray, for treating anaphylaxis.

Study Design

* Hypothesis: FMXIN002 will terminate anaphylactic reactions as effectively-or more rapidly-than IM epinephrine, as measured by clinical parameters.

Study Start Date: June 12

Study Type: INTERVENTIONAL

Condition: Anaphylaxis Food

Intervention: COMBINATION_PRODUCT: Epinephrine 4mg nasal powder spray

Epinephrine nasal powder spray in a unidose nasal applicator device. Will be administered together with a placebo saline I...